Archimedes, Pharmalink deal

Pharmalink received exclusive, worldwide rights to use Archimedes' Targit drug delivery technology for use with Nefecon to treat IgA nephropathy. Pharmalink, which was co-developing Nefecon with Pharmalink under a 2004 deal, now assumes full responsibility for the enteric formulation of a locally acting corticosteroid that downregulates the kidney's inflammatory process. Pharmalink will also acquire equipment and technologies to manufacture Targit capsules for Nefecon. Archimedes retains all rights to Targit outside Nefecon areas of study. Archimedes received an undisclosed upfront payment and is eligible for royalties on Nefecon. ...